Welcome, Introduction, and Baseline Assessment
Real-World Cases and Panel Discussion
Case Discussion 1: Initial Management of ITP: Diagnosis and Treatment Considerations – Dr. Cooper
Case Discussion 2: Clinical Application of New Advances in the Management of Refractory ITP – Dr. McCrae
Panel Discussion: Vaccines / Caring for Special Populations of Patients With ITP/Thrombocytopenia – Dr. Grace
Summary, Final Thoughts, Posteducation Assessment, and Audience Question and Answer
Date / Time
Marriott Marquis Atlanta
Keith R. McCrae, MD
Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland, Ohio, USA
Nichola Cooper, MD
Honorary Consultant Hematologist
London, United Kingdom
Rachael Grace, MD, MMSc
Assistant Professor of Pediatrics
Harvard Medical School
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, USA
The goal of this activity is to improve the knowledge and competence of learners in using new and emerging therapeutic options for patients with ITP.
This program is intended for physicians and other healthcare professionals who care for patients with ITP.
Upon completion of this activity, participants should be able to:
- Identify newly diagnosed patients with ITP who would benefit from intensified therapy to improve remission rates
- Select optimal second or subsequent lines of therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist
- Plan therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, pregnant women, those with COVID-19, chronic liver disease, undergoing a planned medical procedure, or receiving chemotherapy
- Evaluate new clinical trial data and the clinical practice implications of novel targeted therapies in patients with immune thrombocytopenia
- Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.